Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Randomized, Open-Label, Comparative Safety and Efficacy Study of Tipranavir Boosted With Low-Dose Ritonavir (TPV/RTV) Verses Genotypically-Defined Protease Inhibitor/Ritonvair (PI/RTV) in Multiple Antiretroviral Drug-Experienced Patients.

Next Previous
X
Search
Trial Profile

Randomized, Open-Label, Comparative Safety and Efficacy Study of Tipranavir Boosted With Low-Dose Ritonavir (TPV/RTV) Verses Genotypically-Defined Protease Inhibitor/Ritonvair (PI/RTV) in Multiple Antiretroviral Drug-Experienced Patients.

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 17 Sep 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tipranavir (Primary) ; HIV protease inhibitors; Ritonavir
  • Indications HIV-1 infections
  • Focus Therapeutic Use
  • Acronyms RESIST-1
  • Sponsors Boehringer Ingelheim Pharmaceuticals

    • Most Recent Events

    • 02 Jun 2009 Additional trial locations (Canada and Australia) identified as reported by ClinicalTrials.gov.
    • 12 Nov 2008 Status changed from active, no longer recruiting to completed, according to ClinicalTrials.gov.
    • 06 Oct 2008 Planned end date changed from 1 Mar 2009 to 1 Sep 2009, based on information from ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top